Lee J. Helman
#153,066
Most Influential Person Now
Lee J. Helman's AcademicInfluence.com Rankings
Lee J. Helmanphilosophy Degrees
Philosophy
#8541
World Rank
#11948
Historical Rank
Logic
#5570
World Rank
#6978
Historical Rank
Lee J. Helmanbiology Degrees
Biology
#11583
World Rank
#14987
Historical Rank
Molecular Biology
#1797
World Rank
#1826
Historical Rank
Download Badge
Philosophy Biology
Why Is Lee J. Helman Influential?
(Suggest an Edit or Addition)Lee J. Helman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) (1449)
- Insulin-like Growth Factors and Cancer (1995) (788)
- Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism (2007) (750)
- The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis (2004) (705)
- Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations (2010) (559)
- Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators (2004) (517)
- Mechanisms of sarcoma development (2003) (438)
- Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells (2005) (397)
- Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. (2003) (331)
- Rhabdomyosarcoma: an overview. (1999) (330)
- Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. (2009) (313)
- R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. (2011) (287)
- Metastasis-associated differences in gene expression in a murine model of osteosarcoma. (2001) (283)
- Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. (2013) (283)
- Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. (2009) (281)
- Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. (1990) (260)
- Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. (2016) (253)
- Rhabdomyosarcoma – working out the pathways (1999) (252)
- The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts* (1997) (237)
- Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. (2007) (234)
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases (2007) (228)
- Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. (1994) (218)
- Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. (1989) (213)
- Compressing drug development timelines in oncology using phase '0' trials (2007) (208)
- In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. (1994) (208)
- Molecular cloning and primary structure of human glial fibrillary acidic protein. (1989) (207)
- Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. (1988) (195)
- Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. (2005) (195)
- Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. (1992) (194)
- Cediranib for metastatic alveolar soft part sarcoma. (2013) (193)
- An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential (2004) (191)
- The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation (2007) (190)
- Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. (2011) (186)
- Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. (2003) (182)
- Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma (2013) (181)
- Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. (2011) (175)
- Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation (2013) (172)
- The biology behind mTOR inhibition in sarcoma. (2007) (172)
- The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. (2009) (165)
- CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. (2006) (162)
- Recurrent epimutation of SDHC in gastrointestinal stromal tumors (2014) (157)
- Involvement of IGF-II in human cancer. (1996) (157)
- Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. (2008) (151)
- Expression profiles of osteosarcoma that can predict response to chemotherapy. (2005) (145)
- Targeting Cancer Metabolism (2012) (145)
- Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. (2002) (144)
- Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor (2003) (143)
- Insulin-like growth factor II-mediated proliferation of human neuroblastoma. (1991) (137)
- The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. (1992) (136)
- Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. (1977) (136)
- Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. (1988) (134)
- A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas (2008) (133)
- Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. (1994) (126)
- Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma (2014) (123)
- Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. (1990) (123)
- Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). (2017) (121)
- Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells (2003) (118)
- Insulin-like Growth Factor 1 (IGF-1)-induced Twist Expression Is Involved in the Anti-apoptotic Effects of the IGF-1 Receptor* (2001) (110)
- The Role of the Tyrosine Kinase Domain of the Insulin-like Growth Factor-I Receptor in Intracellular Signaling, Cellular Proliferation, and Tumorigenesis (*) (1995) (109)
- Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. (2011) (108)
- Molecular cloning of beta 3 subunit, a third form of the G protein beta-subunit polypeptide. (1990) (106)
- Positively selected enhancer elements endow osteosarcoma cells with metastatic competence (2017) (105)
- Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma (2017) (105)
- Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology (2016) (103)
- Pediatric soft tissue sarcomas (1994) (102)
- Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. (2001) (102)
- Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. (1996) (100)
- Designing Phase 0 Cancer Clinical Trials (2008) (100)
- Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. (2001) (98)
- Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. (2012) (96)
- The new kid on the block(ade) of the IGF-1 receptor. (2004) (95)
- Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis (2002) (95)
- Focus on sarcomas. (2002) (91)
- Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. (2007) (91)
- Targeting the insulin growth factor receptor 1. (2012) (89)
- Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. (2014) (88)
- The role of IGF-1R in pediatric malignancies. (2009) (86)
- A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. (2015) (85)
- The Role of the Insulin‐like Growth Factor‐I Receptor in Cancer (1995) (84)
- XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. (2000) (81)
- Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis (2003) (81)
- Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. (1998) (79)
- Phase 0 Clinical Trials: Conceptions and Misconceptions (2008) (78)
- Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway (2006) (77)
- Role of the IGF-I receptor in mutagenesis and tumor promotion. (1997) (76)
- New Horizons in the Treatment of Osteosarcoma. (2021) (75)
- Targeting glycolysis through inhibition of lactate dehydrogenase impairs tumor growth in preclinical models of Ewing sarcoma. (2019) (72)
- SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma (2015) (72)
- Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin (2009) (71)
- TDAG51 Mediates the Effects of Insulin-like Growth Factor I (IGF-I) on Cell Survival* (2004) (71)
- Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. (1994) (71)
- Osteosarcoma: the same old drugs or more? (2008) (69)
- Molecular Confirmation of Ewing Sarcoma (2001) (69)
- Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. (1989) (69)
- Expression of the Receptor for Type I Insulin-like Growth Factor (IGF1R) in Gastrointestinal Stromal Tumors: An Immunohistochemical Study of 1078 Cases With Diagnostic and Therapeutic Implications (2013) (69)
- Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth (2013) (68)
- Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. (1992) (67)
- dlk, pG2 and Pref-1 mRNAs encode similar proteins belonging to the EGF-like superfamily. Identification of polymorphic variants of this RNA. (1995) (66)
- Thromboembolic events in children and young adults with pediatric sarcoma. (2007) (64)
- Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor. (1996) (63)
- Rhabdomyosarcoma: current challenges and their implications for developing therapies. (2014) (63)
- Loss of imprinting of IGF2 in Ewing's sarcoma. (1995) (63)
- Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway. (1993) (60)
- CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. (2006) (60)
- Testing of new agents in childhood cancer preclinical models: meeting summary. (2002) (60)
- Insulin‐like growth factor type 1 (IGF–1) and IGF binding protein–3 in patients with Ewing sarcoma family of tumors (2001) (60)
- A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. (2002) (59)
- Molecular markers of neuroendocrine development and evidence of environmental regulation. (1987) (58)
- Treatment of Metastatic Osteosarcoma With the Somatostatin Analog OncoLar: Significant Reduction of Insulin-Like Growth Factor-1 Serum Levels (2002) (56)
- Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. (2002) (56)
- Targeting Tumor Specific Translocations in Sarcomas in Pediatric Patients for Immunotherapy (2000) (56)
- Expression of a kinase‐deficient IGF‐I‐R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF‐I‐R (1998) (55)
- Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. (1990) (51)
- p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. (1998) (51)
- Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. (2017) (51)
- Carney triad can be (rarely) associated with germline succinate dehydrogenase defects (2015) (51)
- Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. (2010) (50)
- Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor (2016) (49)
- Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. (2002) (49)
- The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease (2016) (45)
- A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript (2017) (45)
- Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. (2012) (44)
- The Biology of Metastases in Pediatric Sarcomas (2005) (43)
- SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors (2017) (42)
- Insights into pediatric rhabdomyosarcoma research: Challenges and goals (2019) (42)
- Prospects and challenges for the development of new therapies for Ewing sarcoma. (2013) (41)
- Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression12 (2016) (40)
- Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas (2009) (39)
- Chromogranin A expression in normal and malignant human tissues. (1988) (39)
- Rare Tumors in Children: Progress Through Collaboration. (2015) (39)
- A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. (2001) (39)
- All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. (1991) (38)
- IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma1 (2015) (38)
- Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma (2017) (38)
- A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. (2009) (37)
- The sequence of an adrenal specific human cDNA, pG2. (1990) (37)
- Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. (1995) (36)
- Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells (2003) (36)
- Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth (2013) (35)
- An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). (2011) (35)
- Strategies to explore new approaches in the investigation and treatment of osteosarcoma. (2009) (35)
- The First European Interdisciplinary Ewing Sarcoma Research Summit (2012) (34)
- Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. (2016) (34)
- Expression of PAX3 in Ewing's sarcoma family of tumors. (1997) (34)
- Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth (2019) (33)
- Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016) (2019) (33)
- Post-Transcriptional Dysregulation by miRNAs Is Implicated in the Pathogenesis of Gastrointestinal Stromal Tumor [GIST] (2013) (33)
- Concordant Loss of Imprinting of the Human Insulin-like Growth Factor II Gene Promoters in Cancer (*) (1995) (33)
- Chromogranin‐a expression in gastric and colon cancer tissues (1992) (31)
- The molecular biology of pulmonary metastasis. (2006) (31)
- Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. (2006) (31)
- Intramedullary Ewing sarcoma of the spinal cord: consequences of molecular diagnostics. Case report. (2001) (30)
- SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). (2013) (30)
- New Strategies in Ewing Sarcoma: Lost in Translation? (2014) (29)
- AACR Cancer Progress Report 2015 (2015) (28)
- Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. (1991) (28)
- AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma (1998) (27)
- Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma (2014) (26)
- Immune reconstitution prevents metastatic recurrence of murine osteosarcoma (2007) (26)
- SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). (2016) (26)
- Progress in the curative treatment of childhood hematologic malignancies. (2008) (26)
- STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma (2016) (25)
- Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. (2001) (24)
- 1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. (1996) (24)
- Diminished G1 Checkpoint after γ-Irradiation and Altered Cell Cycle Regulation by Insulin-like Growth Factor II Overexpression* (1999) (24)
- Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor (2016) (22)
- Thrombocytopenia and extragonadal germ-cell neoplasm. (1984) (22)
- Suppression of rhabdomyosarcoma growth by fumagillin analog TNP‐470 (1996) (22)
- Diverse roles of insulin-like growth factors in pediatric solid tumors. (1994) (21)
- Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-xL (2010) (20)
- Principles and Practice of Pediatric Oncology (7th ed.) (2015) (20)
- Dilemmas associated with congenital ewing sarcoma family tumors. (2008) (20)
- Insulin-like growth factors stimulate growth and L-cysteine uptake by the intestinal parasite Giardia lamblia. (1994) (20)
- Targeting IGF-1R in the treatment of sarcomas: past, present and future. (2009) (19)
- Molecular Alterations in Pediatric Sarcomas: Potential Targets for Immunotherapy (1998) (19)
- Inguinal hernia in patients with Ewing sarcoma: a clue to etiology. (2000) (19)
- Global Methylation Analysis Identifies PITX2 as an Upstream Regulator of the Androgen Receptor and IGF-I Receptor Genes in Prostate Cancer (2012) (18)
- Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. (1977) (18)
- Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin‐like growth factor I (2009) (17)
- Neuroblastoma cell lines mimic chromaffin neuroblast maturation. (1991) (17)
- Glimpsing the cause of rhabdomyosarcoma (1998) (16)
- EWS-FLI1–regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth (2020) (16)
- Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. (1995) (15)
- Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. (1993) (15)
- Autocrine Transforming Growth Factor-β Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein (2000) (14)
- Molecular approaches in pediatric oncology. (2006) (14)
- Evaluation of the molecular mechanisms involved in the gain of function of a Li‐Fraumeni TP53 Mutation (2005) (14)
- Risk‐Based Therapy for Localized Osteosarcoma (2016) (13)
- Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: The national cancer institute experience (2005) (13)
- IGF-II in the pathogenesis of rhabdomyosarcoma: a prototype of IGFs involvement in human tumorigenesis. (1993) (13)
- High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. (2001) (12)
- CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma (2020) (12)
- Thyroid hormone inactivation in gastrointestinal stromal tumors. (2014) (12)
- Genome-Wide Identification of PAX 3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer (2010) (12)
- Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung (2020) (12)
- A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor (2019) (12)
- New insights into the causes of cancer. (1991) (11)
- Molecular cloning, sequence analysis and mRNA expression of human ADP-ribosylation factor. (1989) (11)
- Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma (2020) (11)
- SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors (2017) (10)
- Telomere stability genes are not mutated in osteosarcoma cell lines. (2005) (10)
- SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma (2020) (10)
- Erratum: The new kid on the block(ade) of the IGF-1 receptor (Cancer Cell 5 (201-202, 231-239)) (2004) (9)
- Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma (1997) (9)
- SLFN 11 is a transcriptional target of EWS-FLI 1 and a determinant of drug response in Ewing ’ s sarcoma (2015) (9)
- Gastrointestinal stromal tumor: psychosocial characteristics and considerations (2012) (9)
- Patterns of proto-oncogene expression: a novel approach to the development of tumor markers. (1987) (8)
- Biallelic expression of all four IGF-II promoters and its association with increased methylation of H19 gene in human brain (1998) (8)
- Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. (2014) (8)
- The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma1 (2016) (7)
- Chromogranin A expression in childhood peripheral neuroectodermal tumors. (1988) (7)
- Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. (1990) (7)
- Succinate dehydrogenase in KIT/PDGFRA wild-type gastrointestinal stromal tumors. (2010) (6)
- Precision Therapy for Pediatric Cancers. (2016) (6)
- Recent Advances in Pediatric Cancer Research (2021) (6)
- Erratum: Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis (Nature Medicine (2002) 8 (1276-1280)) (2003) (5)
- Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis. (2016) (5)
- Cloning of the human chromogranin-A promoter and identification of a sequence that possesses enhancer-like activity (1994) (5)
- A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer. (2018) (5)
- Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome. (2008) (5)
- Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model. (1996) (5)
- Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis. (2015) (4)
- Randomized trial and pharmacokinetic study of pegfilgrastim vs. filgrastim in children and young adults with newly diagnosed sarcoma treated with dose intensive chemotherapy. (2006) (4)
- Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor (2007) (4)
- A Role for Differentiation Arrest in the Development of Neural Crest Tumors (1986) (4)
- IGF-1R inhibition effect on a yes/SFK bypass resistance pathway: Rational basis for cotargeting IGF-1R and yes/SFK kinase in rhabdomyosarcoma. (2014) (4)
- Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. (2010) (4)
- Is Mediated by Insulin-like Growth Factor 11 (1989) (3)
- Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas (2020) (3)
- Targeting pediatric malignancies for T cell-mediated immune responses (2000) (3)
- LRRC15 antibody‐drug conjugates show promise as osteosarcoma therapeutics in preclinical studies (2020) (2)
- Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma (2009) (2)
- Inhibition of murine osteosarcoma lung metastases using the CXCR4 antagonist, CTCE-9908. (2005) (2)
- In vitro and in vivo effects of CXCR4 inhibition in osteosarcoma (2006) (2)
- Correction: Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence (2018) (2)
- Proteomic profiling identifies prognostic subsets in Rhabdomyosarcoma (RMS) (2005) (2)
- Molecular biology of childhood cancers (2015) (1)
- Positively Selected Enhancer Elements Endow Tumor Cells with Metastatic Competence (2017) (1)
- The who and what of imaging in sarcoma and correlation with survival. (2015) (1)
- Evaluation of combined insulin-like growth factor type 1 (IGF1R) and mTOR pathway blockade in sarcoma xenograft models (2007) (1)
- Abstract 1612: Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor (2015) (1)
- Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenome. (2011) (1)
- Abstract 4126: DNA methyltransferase inhibitors target a YES1-YAP1 signaling axis in childhood rhabdomyosarcoma (2018) (1)
- Divergence in Gastrointestinal Stromal Tumor Succinate Dehydrogenase Mutation Underlies Global Epigenomic (2013) (1)
- Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines (2004) (1)
- Abstract 1719: Down-regulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma (2014) (1)
- Abstract #1501: ET-743 modulates EWS-FLi1 activity in Ewing\#8217;s sarcoma cells (2009) (1)
- Developing Therapies Rhabdomyosarcoma : Current Challenges and Their Implications for (2014) (1)
- Effectiveness of chemotherapy in non‐rhabdomyosarcoma soft tissue sarcomas—response (2005) (1)
- Activity of Hsp90-inhibitor drug conjugate (HDC) STA-12-8666 in preclinical models of pediatric sarcoma. (2015) (1)
- A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung. (2013) (1)
- Abstract 2494: Identification of mithramycin analogues with increased potency and more selective inhibition of EWS-FLI1 for the treatment of Ewing sarcoma (2012) (1)
- A Potential Mechanism for Tumorigenesis Regulation of Insulin-like Growth Factor II P 3 Promoter by p 53 : Updated Version (2006) (1)
- 93 – Sarcomas of Soft Tissue* (2014) (1)
- Identification of PDGFR-{beta} activation as a potential bypass resistance pathway in a rhabdomyosarcoma (RMS) model of acquired resistance to IGF-1 receptor blockade. (2014) (0)
- Abstract #5683: Loss of function screen in rhabdomyosarcoma uncovers CRKL: Biological assessment confirms a role in tumor progression in vitro and in vivo (2009) (0)
- Abstract 1930: Evaluating the effect of PARP inhibitors in combination with nicotinamide phosphoribosyltransferase inhibitors in Ewing sarcoma (2017) (0)
- Abstract A46: HSP-90 inhibition in pediatric sarcomas (2014) (0)
- Quantitative analysis of IGF-1R expression in FFPE human rhabdomyosarcoma tumor tissue by mass spectrometry. (2011) (0)
- Identification of TNK2 as a critical kinase in rhabdomyosarcoma through a loss of function shRNA screen. (2012) (0)
- Abstract 1032: Characterizing the metabolic dependencies of rhabdomyosarcoma and Ewing's sarcoma cells (2016) (0)
- Abstract 434: Characterizing the role of serine metabolism in pediatric sarcomas (2017) (0)
- Phosphoprotein pathway mapping: AKT/mTOR activation is negatively associated with childhood Rhabdomyosarcoma survival (2006) (0)
- Abstract 2963: Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. (2013) (0)
- #647 Cytokine regulators of ewing's family of tumors growth: Is there an autocrine loop? (1997) (0)
- Abstract 1632: Suppression of EWS-FLI1 transcription using a combination therapy of mithramycin and cyclin-dependent kinase 9 inhibition (2018) (0)
- Abstract 5714: Targeting serine metabolism impairs tumor growth in preclinical models of Ewing sarcoma (2020) (0)
- Expression profiles of osteosarcoma that can predict metastatic potential (2006) (0)
- Abstract 2497: ET-743 interferes with EWS-FLI1 driven WRN expression in Ewing sarcoma cells and sensitizes to topoisomerase I inhibitors (2012) (0)
- Hereditary Background in Bone and Soft-Tissue Tumours (2002) (0)
- Insulin-Like Growth Factor Signaling in Pediatric Sarcomas (2012) (0)
- Radiographic tumor response in pediatric patients with newly diagnosed localized (LOC) or metastatic (MET) Ewing’s sarcoma (EWS) following neoadjuvant chemotherapy (2007) (0)
- Thromboembolic events (TEE) in children and young adults with sarcoma. (2004) (0)
- Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth. (2010) (0)
- Abstract B19: Tumor-suppressive activities associated to MIR10A-5p expression in developmental sarcomas (2018) (0)
- Abstract 568: Few Carney's Triad patients have mutations in two subunits of the succinate dehydrogenase enzyme (SDHB, SDHC) (2014) (0)
- Abstract 3401: Genetic down-regulation of MET alters the metastatic phenotype of osteosarcoma cells (2010) (0)
- Development of an in vitro model for alveolar soft part sarcoma (ASPS) (2004) (0)
- Oncogenesis of Rhabdomyosarcoma Insulin-like Growth Factor II and PAX 3-FKHR Cooperate in the Updated Version (2006) (0)
- Molecular cloning of fl 3 subunit , a third form of the G protein fl-subunit polypeptide ( signal transduction / molecular cloning ) (0)
- Abstract A09: Targeting Hippo-dependent and Hippo-independent regulation of the YAP1 oncoprotein in childhood rhabdomyosarcoma (2020) (0)
- Cancer Metastasis: Sarcoma (2011) (0)
- Advances in Brief XAGE-1 , A New Gene That Is Frequently Expressed in Ewing ’ s Sarcoma 1 (2000) (0)
- CTOS Board of Directors 2001–2002 (2002) (0)
- Integrated analysis of RNAi screens in pediatric rhabdomyosarcoma. (2013) (0)
- Abstract 4449: Resistance to insulin-like growth factor 1 receptor antibody associated with downregulated IGFBP2. (2013) (0)
- Rationale for Combining with EGFR / HER 2 Inhibitors Growth Factor-1 Receptor Inhibitor ( BMS-536924 ) and The Mechanisms of Differential Sensitivity to an Insulin-like Updated (2008) (0)
- Preface: The Status of Pediatric Solid Tumors in 2015. (2015) (0)
- Abstract 3414: High-throughput screening identifies mithramycin as a potent inhibitor of the EWS-FLI1 transcription factor and a strong cytotoxic agent in Ewing's sarcoma cells (2010) (0)
- Abstract 2008: Ewing sarcoma cells harboring a translocation that retains EWSR1 exon 8 require HNRNPH1 to express the in-frame oncogenic fusion transcript EWS-FLI1 (2016) (0)
- Role of IGF-1R inhibition on an Src-family kinase bypass resistance pathway: A rational basis for cotargeting IGF-1R and Src kinase in pediatric sarcomas? (2017) (0)
- Rhabdomyosarcoma Cell Lines-retinoic Acid Inhibits the Growth of Human trans All-Updated Version (2006) (0)
- Immunomagnetic P urging o f E wing's S arcoma F rom B lood and B one M arrow: Q uantitation b y R eal-Time P olymerase Chain R eaction (2001) (0)
- Sarcomas and malignancies of the bone (2014) (0)
- 252 The DNA damage response gene Schlafen 11 (SLFN11) is a transcriptional target of ETS transcription factors in Ewing's sarcoma and other cancers (2014) (0)
- Abstract C222: The identification of kinase targets in Ewing sarcoma cell lines using RNAi and high-throughput investigational agents screens. (2013) (0)
- Abstract IA33: Combination targeted therapy in pediatric sarcomas (2014) (0)
- Identi fi cation of Mithramycin Analogues with Improved Targeting of the EWS-FLI 1 Transcription Factor (2016) (0)
- Molecular Oncology: Sarcomas (2013) (0)
- Abstract LB-151: Positively selected enhancer elements endow tumor cells with metastatic competence (2016) (0)
- Abstract 479: Inhibition of the splicing of the EWS-FLI1 fusion transcript reverses EWS-FLI1 driven oncogenic expression in Ewing sarcoma (2015) (0)
- Assessing the activity of combining PARP inhibitors (PARPi) and Nicotinamide phosphoribosyltransferase inhibitors (NAMPTi) in Ewing sarcoma (ES). (2016) (0)
- Bone Tumours (2020) (0)
- Abstract 5348: In vivo and in vitro alveolar rhabdomyosarcoma cell growth is affected by TNK2 expression (2011) (0)
- Abstract A103: ET-743 and irinotecan cooperate to inhibit the EWS/FLI1 transcription factor and the associated DNA damage response. (2011) (0)
- Abstract 2211: Quantitative analysis of IGF-1R expression and signaling pathway activation in FFPE xenograft and human tumor tissues (2011) (0)
- Heat-shock protein 90 inhibition in pediatric sarcomas. (2014) (0)
- Abstract LB-171: Collaborating mutations in gastrointestinal stromal tumor (2015) (0)
- Abstract 1597: Inhibition of the novel therapeutic target pregnancy associated plasma protein A (PAPP-A) in Ewing sarcoma enhances efficacy of IGF1R targeting in vivo (2017) (0)
- Ezrin, the cytoskeleton linker protein coordinates cap-dependent translation during metastasis. (2006) (0)
- Abstract C072: Discovery of highly potent and selective covalent inhibitors of FGFR4 (2019) (0)
- Insulin-like growth factors and cytokines in pediatric cancer (1997) (0)
- Abstract 3119: LRRC15, a candidate immunotherapy target, regulates cell-cell interaction, migration and spheroid formation in osteosarcoma cells (2021) (0)
- New Strategies in Ewing ’ s Sarcoma : Lost in Translation ? Running title : New Strategies in Ewing ’ s Sarcoma (2014) (0)
- Succinate Dehydrogenase (SDH) Mutations in Patients with "Wild-Type" (Non-KIT, Non-PDGFRA-Mutated) Gastrointestinal Sarcomas (2010) (0)
- CTOS Board of Directors 1999–2000 (2001) (0)
- Abstract 2331: Loss of LRRC15 in osteosarcoma cells disrupts extracellular matrix integration, intercellular communication, and differentiation (2023) (0)
- Abstract 2635: Role of LRRC15, a candidate immunotherapy target, in cell adhesion, migration and spheroid formation in osteosarcoma cells (2020) (0)
- Abstract 3892: Targeting Hippo-dependent and Hippo-independent regulation of the YAP1 oncoprotein in childhood rhabdomyosarcoma (2020) (0)
- A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma. (2022) (0)
- Histone deacetylase inhibition triggers suppression of the IGF-1R/Akt pathway in rhabdomyosarcoma and Pax3-Foxo1 in alveolar rhabdomyosarcoma (2016) (0)
- Strategic alignment of clinical trials at the National Cancer Institute Center for Cancer Research: Development of the clinical mission and baseline portfolio metrics. (2011) (0)
- Recurrent Osteosarcoma Localized to the Lung (2020) (0)
- Abstract PR08: Lactate dehydrogenase A is a pharmacologically tractable EWS-FLI1 transcriptional target that regulates the glycolytic dependence of Ewing sarcoma (2020) (0)
- Abstract B14: Hsp90-inhibitor drug conjugate STA-12-8666 demonstrates complete tumor regression in preclinical models of pediatric sarcoma (2016) (0)
- Abstract IA04: Targeting the expression of EWS-FLI1 (2018) (0)
- #511 Insulin‐like Growth Factor‐I Receptor is Necessary for EWS/FLI‐1 Induced Transformation of Fibroblasts (1996) (0)
- Reduction of murine osteosarcoma lung metastases using the dipeptidyl peptidase inhibitor talabostat. (2006) (0)
- Breakpoint Pax 3 / FKHR ( der 13 ) t ( 2 ; 13 ) FKHR chromosome 13 Pax 3 chromosome 2 FKHR activation FKHR activation Pax (1999) (0)
- Cancer esearch cular and Cellular Pathobiology ome-Wide Identification of PAX 3-FKHR Binding Sites in bdomyosarcoma Reveals Candidate Target Genes R ortant for Development and Cancer (2010) (0)
- Abstract 651: Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-xL (2011) (0)
- Cytogenetics and experimental models. (1997) (0)
- MOLECULAR CANCER THERAPEUTICS | CANCER BIOLOGYAND TRANSLATIONAL STUDIES EWS-FLI1–regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth (2020) (0)
- 276 INVITED IGF1R Inhibitors in the Treatment of Ewing Sarcomas (2011) (0)
- A simple and rapid UHPLC–MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH‐1473759 in murine plasma (2017) (0)
- Abstract 701: Elevated insulin-like growth factor 1 receptor provides an essential survival signal via Bcl-xLin rhabdomyosarcoma cells as an alternative to Bcl-2 overexpression (2010) (0)
- Abstract 2760: Identification of ET-743 analogs with improved selectivity and potency for EWS-FLI1 and Ewing sarcoma cells. (2013) (0)
- Abstract 520: Functional genomic screens identify microRNA regulators of the oncogenic fusion transcription factor EWS-FLI1 (2014) (0)
- Genome-wide association study identifies novel loci associated with osteosarcoma (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Lee J. Helman?
Lee J. Helman is affiliated with the following schools:
